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Abstract: Device satisfaction and preference are important patient-reported outcomes to 
consider when choosing inhaled therapy. A subset of adults (n = 153) with moderate or severe 
asthma participating in a randomized parallel-group, double-dummy trial that compared the 
efficacy and safety of 12 weeks’ treatment with budesonide delivered via Respimat® Soft Mist™ 
Inhaler (SMI) (200 or 400 µg bd) or Turbuhaler® dry powder inhaler (400 µg bd), completed 
a questionnaire on patient device preference and satisfaction (PASAPQ) as part of a psycho-
metric validation. As the study used a double-dummy design to maintain blinding, patients 
used and assessed both devices, rating their satisfaction with, preference for, and willingness 
to continue using each device. The mean age of patients was 41 years, 69% were female and 
the mean duration of disease was 16 years. Total PASAPQ satisfaction scores were 85.5 and 
76.9 for Respimat® SMI and Turbuhaler® respectively (p  0.0001); 112 patients (74%) pre-
ferred Respimat® SMI and 26 (17%) preferred Turbuhaler®. Fourteen subjects (9%) indicated no 
preference for either inhaler. Willingness to continue using Respimat® SMI was higher than that 
for Turbuhaler® (mean scores: 80/100 and 62/100, respectively). Respimat® SMI was preferred 
to Turbuhaler® by adult asthma patients who used both devices in a clinical trial setting.
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Introduction
A patient’s satisfaction with and preference for an inhaler device are important 
outcomes to consider when choosing inhaled therapy for patients with asthma and 
chronic obstructive pulmonary disease (COPD). Patient satisfaction is important in 
determining whether patients persist with medication,1 and has been shown to be influ-
enced by such things as the process of taking or using the product and its subsequent 
outcomes.2 Among healthcare professionals, both the ease of use and patient prefer-
ence for an inhaler device are regarded as amongst the most important considerations 
when selecting an inhaler for patients.3,4
Using inhaler devices to treat obstructive lung diseases is by no means a straightforward 
process for patients, who must learn how to prepare and operate them before being able to 
take the medication as prescribed. Furthermore, it is also clear that not all patients can use 
all inhalers equally well. They clearly vary in their preferences for different inhalers5,6 and 
frequently do not see devices as being interchangeable. Although a large range of inhaler 
devices is now available, established devices such as the pressurized metered-dose inhaler 
(pMDI) and the dry powder inhaler (DPI) are still the most frequently used. The pMDI is 
robust and can be simple to use, although many patients have trouble using it correctly, International Journal of COPD 2009:4 226
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particularly in co-ordinating the actuation of the device with 
inhalation,7,8 a disadvantage that prompted the development 
of breath-actuated pMDIs. With DPIs, the co-ordination 
challenge can be avoided, but a minimum inspiratory flow is 
required which may be limiting for some patients, particularly 
young children,9 and some multidose designs need to be stored 
in a dry place to prevent moisture degrading the powder. One 
popular multidose design is the Turbuhaler®, which has been 
shown to deliver a high proportion of the inhaled dose in the 
form of fine particles.10
Respimat® Soft Mist™ Inhaler (SMI) (Figure 1) is a new 
type of propellant-free inhaler that generates a fine aerosol 
cloud which is emitted more slowly and lasts 4 to 10 times 
longer than the aerosol from pressurized metered-dose inhalers 
(pMDIs).11 This device has been shown to deliver a higher 
proportion of the emitted dose to the lungs than a pMDI,12–14 
and this allows patients to take a lower nominal dose of 
bronchodilator (relative to pMDI) without affecting efficacy 
or safety, in both asthma and COPD.15–17 Lung deposition from 
Respimat® SMI was also found to be greater than from Turbu-
haler® in asthma patients.14 In a controlled clinical trial, COPD 
and asthma patients found Respimat® SMI easy to use and 
preferred it to a hydrofluoroalkane (HFA)-propelled MDI.6
The objective of the current study was to compare 
the level of patient satisfaction with Respimat® SMI and 
Turbuhaler®. This analysis was performed on a subset of 
patients who had participated in a multicenter clinical trial 
(Boehringer-Ingelheim study #1047.16 – data on file). 
The vast majority of patients studied were familiar with 
and using the pMDI, only a minority having had prior 
experience with the Turbuhaler® and none having used 
Respimat® SMI before. In the original clinical trial, all 
subjects were instructed in the proper use of the Respimat® 
SMI, Turbuhaler®, and pMDI devices. Performance and 
convenience of the devices were assessed by means of 
a questionnaire specifically designed to measure patient 
satisfaction with inhaler devices (Patient Satisfaction and 
Preference Questionnaire; PASAPQ).18 In the original trial, 
peak expiratory flow was the primary clinical endpoint and 
no clinically significant difference was observed between 
test groups at end of study.
Methods
study design
The study presented in this article was undertaken in a subset 
of adults with clinically stable moderate or severe asthma 
who had taken part in a randomized, parallel-group, placebo-
controlled, double-blind, multicenter clinical trial. The subset 
chosen for the current analysis consisted of 153 English-
speaking and German-speaking patients (from study centers 
in Canada, Germany and South Africa), selected because the 
PASAPQ questionnaire was only available in those languages. 
The aim of the primary trial was to compare the efficacy and 
safety of 12 weeks’ treatment with budesonide delivered either 
via Respimat® SMI or Turbuhaler®. The efficacy and safety 
results of the clinical trial are reported separately (Boehringer-
Ingelheim, study #1047.16 – data on file).
As the Respimat® SMI and Turbuhaler® are different in 
appearance, a double-dummy design was used; thus, patients 
used both devices for the full duration of the trial. All patients 
were randomly allocated to study treatment with budesonide 
for 12 weeks according to one of the three regimens shown 
in Table 1. For all regimens, patients took 2 inhalations 
twice daily from both of the devices, resulting in total daily 
budesonide dosages of either 400 or 800 µg. The order in 
which patients used the two inhalers on each day of the study 
was determined by a separate random allocation step.
Patients
To be enrolled into the screening phase of the clinical study, 
men and women aged 18–65 years had to have a diagnosis 
of moderate or severe asthma of at least 6 months’ duration, 
be a non-smoker or ex-smoker (stopped at least 1 year before 
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Figure 1 schematic diagram of respimat® soft Mist™ Inhaler. Courtesy of Boehringer 
Ingelheim gmbH.International Journal of COPD 2009:4 227
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screening and with a history of no more than 10 pack-years), 
and be receiving either a) high-dose inhaled corticosteroids 
(ICS) plus short-acting beta2-agonist as needed, with or 
without other asthma medications such as long-acting beta2-
agonists, or b) low-dose ICS plus either inhaled long-acting 
beta2-agonists or oral xanthines.
During a run-in period of 1–3 weeks, ICS dosage was 
standardized to beclomethasone dipropionate 400 µg/day 
delivered via pMDI, plus salbutamol via pMDI for rescue 
use as needed.
To enter the study itself (randomized treatment phase), 
patients had to fulfill a second set of criteria based on 
spirometry and record card data. Forced expiratory volume 
in 1 second (FEV1) had to be 50% to 81% of predicted and 
either FEV1 or peak expiratory flow (PEF) had to be at least 
10% lower than the screening visit value. In addition, at least 
one of the following diary card criteria had to be met (for at 
least 2 out of 7 days, based on the most recent 7 consecutive 
days of the run-in period): morning PEF  80% predicted; 
diurnal PEF variability  20%;  6 inhalations/day of 
beta2-agonist, and asthma symptom scores of 2 (day) 
or 1 (night).
Assessments
At the end of the 12-week treatment period, all patients rated 
the two devices using the Patient Satisfaction and Preference 
Questionnaire (PASAPQ). The PASAPQ is a multi-item 
measure of satisfaction and preference with inhaler devices 
that is designed to be easy to understand and administer to 
asthma and chronic obstructive pulmonary disease (COPD) 
patients. The items were developed using literature search, 
focus groups and expert opinion, and the resultant question-
naire has been confirmed to have validity, reliability and 
responsiveness in psychometric analyses.18
The PASAPQ is self-administered and contains 13 
satisfaction items grouped into two domains, performance 
and convenience, that together constitute the total score 
(Table 2). These items are measured on a Likert-type 
response scale from 1 (very dissatisfied) to 7 (very satisfied). 
The three other items are an overall satisfaction question, 
also measured on the 1 to 7 scale, a question on preference 
(selection between devices, as well as a “no preference” 
option) and a question on willingness to continue using the 
device in the future, measured on scale of 0 (not willing) 
to 100 (definitely willing). As this study provided data for the 
psychometric analyses, 46 additional questions were included 
for these purposes,18 but these did not contribute to the total 
or domain PASAPQ scores reported in this paper.
Domain and total scores are first summed and then trans-
formed to scores on a scale from 0 (least) to 100 (most) for 
patients who complete at least half of the questions. If the 
patient completes at least half of the items in a domain, values 
for missing items are imputed using the mean of the completed 
items in that domain (the “half-scale rule”).19 The total score can 
be calculated only when both domain scores have computable 
scores and is calculated as the sum of the 13 items after substi-
tution for missing items at the domain level has taken place. In 
other research,18 estimates of the minimal important difference 
(MID) for the PASAPQ had demonstrated that a score differ-
ence between test inhalers of 8 to 10 points on the domain and 
total scores represented a medium difference in effect, and a 
difference of 3 to 6 points represented a small difference in 
effect, depending on which domain was measured. For the 
current study, therefore, a score difference of 10 points 
was considered to represent an important difference, and the 
Table 1 Treatment arms in the clinical study showing the double-
dummy design
Treatment 
arm
Respimat® SMI Turbuhaler®
1 Budesonide 100 µg 
per puff
Placebo
2 Budesonide 200 µg 
per puff
Placebo
3 Placebo Budesonide 200 µg per puff
Table 2 Items in Patient satisfaction and Preference Questionnaire 
(PAsAPQ)
Device 
attribute
Question Scoring
Performance Overall feeling of inhaling each contributes  
equally to total  
PAsAPQ score
Inhaled dose goes to lungs
Amount of medication left
Works reliably
ease of inhaling a dose
Using the inhaler
speed medicine comes out
Convenience Instructions for use
size of inhaler
Durability of inhaler
ease of cleaning inhaler
ease of holding during use
Convenience of carrying
Other Overall satisfaction stand alone questions  
(each scored  
independently)
Preference
Willingness to continueInternational Journal of COPD 2009:4 228
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number of patients who scored one inhaler higher than the other 
by 10 points was recorded for each domain separately and 
for the total PASAPQ score.
For half of the patients, the questionnaires had Respimat® 
SMI listed first and for the other half, the Turbuhaler® 
device was listed first, the order of device listing being 
randomly allocated.
statistical analysis
In addition to descriptive statistics, the mean PASAPQ satis-
faction scores and willingness-to-continue ratings (the latter 
expressed as least squares means) were tested for statistically 
significant differences between the two devices using a SAS 
general linear model with a nested design. Comparisons of 
individual items were tested using a paired t-test. Difference 
in preference was analyzed using a chi-square test. The 5% 
level of significance was used (two-tailed test).
Results
Patient demographics and PAsAPQ 
response rates
The mean age of patients in the subset was 41.0 years 
(standard deviation [SD], 11.5 years), 106 (69.3%) were 
women and the mean duration of asthma was 16.1 years 
(SD, 12.5 years). Before entering the trial, 30 patients had 
previously received inhaled treatment via Turbuhaler® and 
no patients had used Respimat® SMI. In the original data set, 
306 subjects responded to the PASAPQ and 299 completed 
the full questionnaire (7 subjects left at least one item missing 
but had computable scores). There were no unusable ques-
tionnaires. For the purposes of the comparison between the 
Respimat® SMI and Turbuhaler®, PASAPQ satisfaction scores 
were calculated for all 153 patients in the relevant subset, of 
whom 152 responded to the preference question.
satisfaction with device performance 
and convenience
For the total PASAPQ score and the performance domain 
score, mean scores for Respimat® SMI were significantly 
higher than those for Turbuhaler® (p  0.0001, general 
linear models analysis). The mean scores for the convenience 
domain also showed a numerical superiority for Respimat® 
SMI, but the difference between devices was not statistically 
significant (Figure 2). Analysis by country also showed 
total PASAPQ score and performance domain score to be 
significantly higher for Respimat® SMI in each case (data 
not shown).
Comparison of scores by item showed that in the perfor-
mance domain, mean scores for Respimat® SMI for all ques-
tions were significantly higher than those for Turbuhaler® 
(p  0.0001, paired t-test) with mean differences between 
device scores ranging from 0.6 to 1.4. In the convenience 
domain, the mean differences between device scores were 
smaller (range, −0.2 to 0.2) and generally not of statistical 
significance, with the difference favoring Respimat® SMI for 
four items and Turbuhaler® for two (Table 3).
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Figure 2 Mean patient device preference and satisfaction (PAsAPQ) scores for each device (all countries combined), with range of scores transformed to 0 to 100 points; 
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For the total PASAPQ satisfaction score, 60 patients 
(39.2%) gave a higher score for Respimat® SMI than for 
Turbuhaler® that also exceeded the pre-defined threshold 
of 10 points representing an important difference. For the 
performance and convenience domains, the corresponding 
patient numbers were 79 (51.6%) and 18 (11.8%). This pat-
tern of results was similar across the three countries (data 
not shown). No patients gave a score for Turbuhaler® that 
exceeded the Respimat® SMI score by more than 10 points 
(Figure 3).
Preference and willingness to continue
Respimat® SMI was preferred by 112 of 152 patients (73.7%) 
and Turbuhaler® preferred by 26 (17.1%), while 14 patients 
(9.2%) expressed no preference for either inhaler (Figure 4). 
When these proportions were restated with the subset of 
patients who indicated a preference for one device as the 
denominator, 81.2% preferred Respimat® SMI and 18.8% 
preferred Turbuhaler®, a difference that was statistically 
significant (p  0.0001). In the small group of patients who 
had used Turbuhaler® previously, preference for Respimat® 
SMI was still markedly higher than for Turbuhaler®, with 
20% of patients expressing no preference (Table 4).
The least squares mean score on the willingness-to-continue 
question for Respimat® SMI was 79.9, significantly higher than 
the mean score for Turbuhaler® (61.8; p  0.0001).
Discussion
In a group of patients with moderate or severe asthma who 
had just completed a clinical trial, satisfaction with device 
performance was significantly higher with Respimat® 
SMI than with Turbuhaler® as measured by the PASAPQ. 
Patient satisfaction with the convenience of the two devices 
was similar. When patients were asked which device they 
preferred, just over 80% of those who expressed a definite 
preference preferred Respimat® SMI.
Our findings are consistent with those of a randomized 
crossover study in which 224 COPD and asthma patients 
who were regular users of pMDIs received combination 
bronchodilator therapy (ipratropium plus fenoterol) via 
Respimat® SMI and pMDI for 7 weeks each.6 In that trial, 
as in our analysis, both total PASAPQ satisfaction score 
and performance domain score were significantly higher 
for Respimat® SMI, patient preference significantly favored 
Respimat® SMI (72%, versus 17% for pMDI) and patients 
were significantly more willing to continue using Respimat 
SMI after the study than pMDI.6
The aerosol produced by Respimat® SMI is generated 
mechanically by a spring when the user actuates the inhaler 
by pressing the dose-release button. Co-ordination of 
actuation with the patient’s inspiratory breath is an easier 
task than with the standard pMDI, because the aerosol 
cloud from Respimat® SMI is emitted more slowly and 
Table 3 satisfaction with inhaler attributes in performance and convenience domains
Domain and inhaler attribute Respimat® SMI Turbuhaler® Difference, Respimat®− 
Turbuhaler®
n Mean (SD) n Mean (SD) n Mean (SD) p value1
Performance domain  
  Overall feeling of inhaling the medicine
    Feeling that the inhaled dose goes to the 
lungs
    Can tell amount of medication left in 
container
  Inhaler works reliably
  ease of inhaling a dose
  Using the inhaler
  speed of medication coming out of inhaler
 
153  
 
153  
 
153  
153  
153  
151  
151
 
6.0 (1.3)  
 
6.3 (1.2)  
 
6.0 (1.4)  
6.4 (0.9)  
6.3 (1.1)  
6.3 (1.1)  
6.3 (1.1)
 
153   
 
153   
 
153   
153   
152   
151   
151
 
5.2 (1.6)  
 
4.9 (1.8)  
 
4.7 (1.8)  
5.5 (1.6)  
5.7 (1.5)  
5.7 (1.5)  
5.6 (1.5)
 
153  
 
153  
 
153  
153  
152  
151  
151
 
0.8 (2.0)  
 
1.4 (2.0)  
 
1.3 (1.9)  
1.0 (1.7)  
0.7 (1.7)  
0.6 (1.6)  
0.7 (1.8)
 
0.0001  
 
0.0001  
 
0.0001  
0.0001  
0.0001  
0.0001  
0.0001
Convenience domain  
  Instructions for using the inhaler
  size of the inhaler
  Durability of the inhaler
  ease of cleaning the inhaler
    ease of holding inhaler during use  
Overall convenience of carrying inhaler
 
152  
153  
153  
153  
151  
151
 
6.1 (1.1)  
5.7 (1.4)  
6.3 (1.0)  
5.9 (1.1)  
6.3 (1.0)  
5.8 (1.3)
 
152   
153   
153   
153   
151   
151
 
6.0 (1.2)  
5.9 (1.2)  
6.1 (1.2)  
5.8 (1.2)  
6.1 (1.0)  
5.9 (1.2)
 
152  
153  
153  
153  
151  
151
 
0.1 (0.9)  
−0.2 (0.9)  
0.2 (0.9)  
0.1 (0.8)  
0.2 (1.0)  
−0.1 (0.9)
 
0.0893  
0.0045  
0.0096  
0.0881  
0.0064  
0.2462
Overall satisfaction with inhaler 151 6.2 (1.1) 151 5.6 (1.6) 151 0.6 (1.7) 0.0001
1By paired t-test.
Abbreviations: sD, standard deviation; sMI, soft mist inhaler.International Journal of COPD 2009:4 230
Hodder et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
so is longer-lasting (1.5 seconds, compared with 0.15 to 
0.36 seconds for typical pMDIs).11 No co-ordination of actua-
tion with inhalation is necessary with the Turbuhaler®, but 
as with other DPIs, generation of an aerosol from the device 
relies on the energy of the patient’s own inspiratory effort. 
This would not normally pose a difficulty to an adult asthma 
patient with stable disease, even if he or she was experiencing 
bronchoconstriction.20 Nevertheless, a comparison of scores 
for individual items in our study suggested that the difference 
in aerosol production method between the test devices was 
apparent to patients. This comparison also confirmed that 
for all aspects of device performance, patients were signifi-
cantly more satisfied with Respimat® SMI than Turbuhaler®. 
The largest score differences were for the “feeling that the 
inhaled dose goes to the lungs” and the ability to tell how 
much medication remains in the inhaler. Other attributes 
that scored significantly better for Respimat® SMI included 
the overall feeling of inhaling, the ease of inhaling a dose 
and the speed at which medication comes out of the inhaler. 
There was much less difference between the two devices in 
the level of satisfaction with convenience attributes such as 
size, portability and handling.
The use of patient-reported outcomes (PROs) for 
assessing the effectiveness of products for regulatory 
approval is a developing phenomenon.21 Although device 
satisfaction and preference is a valid patient-reported 
outcome, it is less studied than other PROs like quality of 
life.22 In a recent review of 30 published inhaler preference 
studies, only two studies were found to have used robust 
instruments for measuring preference and satisfaction.22 The 
two instruments in question, the Patient Device Experience 
Assessment (PDEA)23 and the Patient Satisfaction and 
Preference Questionnaire (PASAPQ),18 were developed by 
experts in psychometric testing and subjected to field testing. 
Of these, only the PASAPQ has a published validation18 
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which also included a determination of the minimum impor-
tant difference between devices, allowing an assessment of 
the clinical significance of differences observed in testing. 
For this reason we chose to use the PASAPQ as the preference 
assessment tool for the current study. Of 97 patients (63% 
of the sample) who gave higher total PASAPQ satisfaction 
scores to Respimat® SMI than Turbuhaler®, the score differ-
ence met the pre-defined criterion for the minimum important 
difference (10 points) in 60 patients, nearly 40% of all 
those in the study. The score difference did not meet this 
criterion in any patient who gave Turbuhaler® a higher total 
satisfaction score than Respimat® SMI. In our analysis, the 
mean willingness-to-continue score after the 12-week study 
period was nearly 80 out of 100 for Respimat® SMI, but just 
over 60 out of 100 for Turbuhaler®.
The time-honored paradigm that inhaler preference will 
lead to improved medication adherence and consequently 
to better clinical outcomes seems plausible, but has been 
difficult to prove.21 Treatment satisfaction has been shown 
to be associated with the probability that patients would 
persist with a prescribed medication1 and at least in theory, 
patients might be able to achieve better inhaler technique 
with a device they find more satisfying to use, thus improv-
ing the effectiveness of the inhaled drug regimen. Recent 
evidence supporting the preference–adherence–outcome 
paradigm is beginning to emerge, as it does appear that in 
real life conditions, choice of inhaler device can have an 
impact on treatment adherence and disease control, and that 
the patient/device interface is crucial, for both asthma24–25 
and COPD.26–28
The design of our study reduced the possible sources of 
bias that could affect the patients’ assessments of satisfaction 
with the two devices. The same active ingredient was deliv-
ered by both devices, as recommended in a review of device 
preference and satisfaction studies by Anderson.22 Deposition 
of budesonide in asthma patients was shown to be signifi-
cantly higher with Respimat® SMI than Turbuhaler® when 
both were used with optimal technique (51.6 and 28.5% of 
ex-valve dose respectively),14 but if this, or the use of two 
different doses in Respimat® SMI had resulted in a discernible 
efficacy difference over the period of our study, patients could 
not have attributed the difference to a single device because 
of the double-dummy design that was employed. In addi-
tion, in the original clinical trial, no significant difference in 
the primary outcome measure of peak expiratory flow was 
detected between groups. For some patients, the novelty of a 
new type of inhaler might translate into short-term expressed 
preference over a familiar device such as the pMDI. However, 
because the majority of patients in our study were naïve to 
both Respimat® SMI and Turbuhaler®, this would probably 
not have affected the observed preference in favor of the 
Respimat® SMI. The use of the PASAPQ also helped to reduce 
bias, since the questions in it were designed to be specific to 
attributes of the inhaler rather than the treatment.
In summary, adults with asthma who used Respimat® SMI 
and Turbuhaler® devices in a clinical trial setting reported 
significantly greater satisfaction with the performance of 
Respimat® SMI, and the level of patient satisfaction with 
convenience of these two devices was very similar. This 
translated into a higher preference for Respimat® SMI, and 
a greater willingness to continue using it, compared with 
the Turbuhaler®.
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